Patents by Inventor Kevin Hamblett

Kevin Hamblett has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20210346508
    Abstract: Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR ?3.9 when administered at the same toxin dose.
    Type: Application
    Filed: March 23, 2021
    Publication date: November 11, 2021
    Inventors: Kevin Hamblett, Rupert H. Davies, James R. Rich, Gerald J. Rowse, Vincent K.C. Fung, Stuart D. Barnscher
  • ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20210260210
    Abstract: Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR ?3.9 when administered at the same toxin dose.
    Type: Application
    Filed: March 12, 2019
    Publication date: August 26, 2021
    Inventors: Kevin HAMBLETT, Rupert H. DAVIES, James R. RICH, Gerald J. ROWSE, Vincent K.C. FUNG, Stuart D. BARNSCHER
  • Anti-HER2 biparatopic antibody-drug conjugates and methods of use
    Patent number: 11000598
    Abstract: Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR?3.9 when administered at the same toxin dose.
    Type: Grant
    Filed: October 7, 2019
    Date of Patent: May 11, 2021
    Assignee: Zymeworks Inc.
    Inventors: Kevin Hamblett, Rupert H. Davies, James R. Rich, Gerald J. Rowse, Vincent K. C. Fung, Stuart D. Barnscher
  • ANTI-HER2 BIPARATOPIC ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
    Publication number: 20200108152
    Abstract: Anti-HER2 biparatopic antibody-drug conjugates (ADCs) in which the drug is an auristatin analogue and is conjugated to the antibody at a low average drug-to-antibody ratio (DAR), and methods of using the ADCs in the treatment of a HER2-expressing cancer. The low average DAR (<3.9) ADCs as described herein have improved tolerability and decreased toxicity as compared to a corresponding ADC having a DAR?3.9 when administered at the same toxin dose.
    Type: Application
    Filed: October 7, 2019
    Publication date: April 9, 2020
    Inventors: Kevin Hamblett, Rupert H. Davies, James R. Rich, Gerald J. Rowse, Vincent K.C. Fung, Stuart D. Barnscher